Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Melanoma: early-phase trial registry
89 of 269 indexed Melanoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #36 of 28,707 conditions by registered trial count.
269 US clinical trials · 89 currently recruiting · #36 of 28,707 conditions by registered trial count
Melanoma: 269 US clinical trials tracked, 89 recruiting.
Melanoma is the subject of 269 registered US clinical trials on ClinicalTrials.gov, 89 of them currently open to new participants. 19 are in Phase 3-4 (later-stage) and 184 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 20 of these trials.
Enrollment posture brief
Registry condition melanoma
OPEN 89 | RECR 33% | LATE 19 | EARLY 184 | RANK #36 | SPON 20
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Melanoma lists 89 open slots (33% of 269 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Melanoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Melanoma is recruiting below its size-band peers.
89 of 269 indexed trials (33.1%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Melanoma trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 20 of 269 trials (7.4%). 139 distinct sponsors appear on at least one study for this condition label.
-
Typical Melanoma enrolment sits around 72 participants.
Median target enrolment is 72 among the 267 trials that report a genuine target (sentinel values excluded). 155 of those (58.1%) plan for fewer than 100 participants.
-
Melanoma research is mostly interventional.
231 interventional and 38 observational studies make up this index (85.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
269 total, page 1 of 6
War on Melanoma™ Public Health & Education Campaign
OHSU Knight Cancer Institute
NCT04611568
Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
M.D. Anderson Cancer Center
NCT01772771
Sample Collection for Ongoing Research and Product Evaluation Study
Natera
NCT07318051
Evaluation for NCI Surgery Branch Clinical Research Protocols
National Cancer Institute (NCI)
NCT00001823
Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of Treatment
Vanderbilt-Ingram Cancer Center
NCT01205815
Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma
National Cancer Institute (NCI)
NCT00040352
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Wake Forest University Health Sciences
NCT06418204
Well-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic
M.D. Anderson Cancer Center
NCT04474301
Video Education With Result Dependent dIsclosure
Dana-Farber Cancer Institute
NCT05225428
A Storage Facility for Tissues Obtained From Patients With Malignant Melanoma
Ohio State University Comprehensive Cancer Center
NCT04567706
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
NCT04895709
A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care
Dana-Farber Cancer Institute
NCT02279004
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
NCT06172478
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
Iovance Biotherapeutics
NCT05727904
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Regeneron Pharmaceuticals
NCT06246916
Molecular Analysis of Childhood and Adolescent Melanocytic Lesions
St. Jude Children's Research Hospital
NCT02775643
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
Memorial Sloan Kettering Cancer Center
NCT05053230
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
Diwakar Davar
NCT07223424
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech
NCT05581004
BostonGene and Exigent Genomic INsight Study
BostonGene
NCT06272864
MySmartSkin Online Skin Self-exam Intervention for Melanoma Survivors
Rutgers, The State University of New Jersey
NCT05373823
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Merck Sharp & Dohme
NCT02332668
Studying Quality of Life Inclusive of Mental Health and Cognitive Behavioral Therapy for Cancer Distress for the Improvement of Quality of Life in Stage III-IV Melanoma Patients
Mayo Clinic
NCT07379138
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Simcha IL-18
NCT04787042
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
Pfizer
NCT05355701
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
M.D. Anderson Cancer Center
NCT03941756
A Study of MGC026 in Participants With Advanced Solid Tumors
MacroGenics
NCT06242470
Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy
Wake Forest University Health Sciences
NCT05703269
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
Regeneron Pharmaceuticals
NCT06413680
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
Nested Therapeutics
NCT06326411
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
Ipsen
NCT06305247
In Vivo Liquid Biopsy of Melanoma (Cytophone)
Cytoastra
NCT06488365
A Study of IBI363 in Subjects with Advanced Solid Malignancies
Innovent Biologics (Suzhou) Co.
NCT06281678
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
BioInvent International AB
NCT04752826
A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors
Shanghai Henlius Biotech
NCT07160335
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
National Cancer Institute (NCI)
NCT02621021
Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma
M.D. Anderson Cancer Center
NCT04594187
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
CJ Bioscience
NCT05877430
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Children's Oncology Group
NCT04851119
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma
NCT06362369
Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
M.D. Anderson Cancer Center
NCT04751396
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
Pfizer
NCT05538130
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
National Cancer Institute (NCI)
NCT02830724
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
NYU Langone Health
NCT05428007
Dabrafenib and/or Trametinib Rollover Study
Novartis Pharmaceuticals
NCT03340506
Digital Remote Monitoring of Immune Checkpoint Inhibitor Therapy Induced Toxicity Using the Vigilant App
Mayo Clinic
NCT06675643
A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
Ravi Amaravadi, MD
NCT04464759
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
H. Lee Moffitt Cancer Center and Research Institute
NCT06295159
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
Vyriad
NCT04291105
IDOV-Immune for Advanced Solid Tumors
ViroMissile
NCT06910657
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 117 |
| Phase 2 | 67 |
| Phase 3 | 16 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Melanoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Melanoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Melanoma page
269 registered trials, 89 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 89 Melanoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Melanoma trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Melanoma condition card totals 269 registered trials; most-linked intervention Ipilimumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.